Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FGF8 Biologics Sequence Review Report 2026: Fibroblast growth factor 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF23 Biologics Sequence Review Report 2026: Fibroblast growth factor 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF22 Biologics Sequence Review Report 2026: Fibroblast growth factor 22 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF20 Biologics Sequence Review Report 2026: Fibroblast growth factor 20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF14 Biologics Sequence Review Report 2026: Fibroblast growth factor 14 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF13 Biologics Sequence Review Report 2026: Fibroblast growth factor 13 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF12 Biologics Sequence Review Report 2026: Fibroblast growth factor 12 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF11 Biologics Sequence Review Report 2026: Fibroblast growth factor 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
491
492
493
494
495
>>
1905
>